Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 USA
Post by: Tina Gaines
Representatives from Elanco Animal Health will be on hand to ofﬁcially open the doors to its new autogenous poultry vaccine facility in Winslow, Maine, on Wednesday, May 3, 2017 at 1:30 p.m. EST.
The ﬁrst of its kind for Elanco, the new state-of-the-art facility is dedicated solely on manufacturing customized, high-quality inactivated vaccines for the poultry industry that will assist in the prevention of unique disease challenges and protection from food safety issues that can’t be addressed with commercially available vaccines.
“Elanco autogenous vaccines are different than commercial vaccines,” explains Milson Gondim, Vice President of Vaccine Operations Manufacturing for Elanco. “We manufacture these vaccines using ﬂock- speciﬁc serotypes not found in commercial vaccines, which gives us the ability to provide poultry producers with disease prevention and food safety solutions unique to their speciﬁc operation.”
According to Tim Hopson, Elanco Poultry District Sales Manager, the new dedicated autogenous facility reﬂects Elanco’s on-going commitment to meet customers’ needs long term.
“The poultry industry needs solutions that go beyond one size ﬁts all,” says Hopson. “The new facility here in Winslow reﬂects our commitment to providing our customers with the solutions they need to be productive, sustainable and profitable for years to come.”
In addition to autogenous vaccine production, the Winslow facility is also the only location in the U.S. that produces commercial live and inactivated poultry vaccines for Elanco.
“So, whether our customers require a commercial vaccine or one that is customized, this new facility will enhance Elanco’s ability to meet their needs,” says Gondim.
Media is welcome to attend the grand opening of the new facility, which is located at 375 China Road, Winslow, Maine.
Elanco provides comprehensive products and knowledge services to improve animal health and food animal production in more than 70 countries around the world. We value innovation, both in scientiﬁc research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenﬁeld, Indiana. Visit us at Elanco.com
Elanco and the diagonal bar logo are trademarks of Eli Lilly and Company or its afﬁliates.
©2017 Eli Lilly and Company or its affiliates. Vacc 6121-3| USPBUAVP00061
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.